Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer

Annals of Surgery

Volumn 241, Issue 6, 2005, Pages 941-947

  Heslin, Martin J ^a,b   Hawkins, Ashley ^a   Boedefeld, William ^a   Arnoletti, J Pablo ^a   Frolov, Andrey ^a   Soong, Richie ^a   Urist, Marshall M ^a   Bland, Kirby I ^a   Merchant, Nipun ^b   Chung, Dai H ^b   Townsend Jr , Courtney M ^b  

^a Kentucky   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; CELECOXIB; GENE PRODUCT; RNA;

ADULT; APOPTOSIS; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR CELL CULTURE; TUMOR GROWTH; WILCOXON SIGNED RANKS TEST;

ADENOMA; APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; BLOTTING, WESTERN; CARCINOMA; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DOWN-REGULATION; EICOSANOIDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LINOLEIC ACIDS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 21144442338     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000164177.95620.c1     Document Type: Conference Paper

References (24)

1. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991; 266:12866-12872.
2. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61:6307-6312.
3. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
4. Dubois RN, Shao J, Tsujii M, et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 1996;56:733-737.
5. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut. 1994;35:675-678.
6. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Phys. 1998;274(Pt 1):G1061-G1067.
7. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997;99:2254-2259.
8. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94:3336-3340.
9. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56:2556-2560.
10. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409-412.
11. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.
12. Bronstein JC, Bull AW. The correlation between 13-hydroxyoctadecadienoate dehydrogenase (13-HODE dehydrogenase) and intestinal cell differentiation. Prostaglandins. 1993;46:387-395.
13. Shureiqi I, Wojno KJ, Poore JA, et al. Decreased 13-S- hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999;20:1985-1995.
14. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates non-steroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60:6846-6850.
15. Blanquicett C, Johnson MR, Heslin M, et al. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem. 2002;303:209-214.
16. Baron JA. Aspirin and cancer. Prev Med. 1995;24:121-124.
17. Baron JA, Cole BF, Sandier RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
18. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
19. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994;91:3228-3232.
20. Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110-3116.
21. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997;57:2909-2915.
22. Bull AW, Branting C, Bronstein JC, et al. Increases in 13-hydroxyoctadecadienoic acid dehydrogenase activity during differentiation of cultured cells. Carcinogenesis. 1993;14:2239-2243.
23. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA. 2003;100:9968-9973.
24. Liu C, Xu D, Sjoberg J, et al. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res. 2004;297: 61-67.